Moleculin Biotech, Inc. filings document regulatory disclosures for a Delaware clinical-stage pharmaceutical company focused on drug development and commercialization. Recent Form 8-K reports cover Regulation FD releases, investor presentations, financial results, clinical and preclinical updates for Annamycin, and intellectual-property matters involving liposomal Annamycin.
The filing record also includes capital-structure and governance disclosures tied to warrant exercise inducement arrangements, warrant-related share issuance, and stockholder voting matters. Definitive proxy materials and voting results describe special-meeting proposals, including Nasdaq-related approval for warrant shares and charter-related governance items, while exhibit filings attach press releases, presentation materials, and other public-company disclosures.
Moleculin Biotech, Inc. filed Amendment No. 1 to its Annual Report for the year ended December 31, 2025 to add Part III information on directors, executive compensation, ownership and auditor matters. The amendment does not change prior financial statements.
The company reports aggregate market value of voting equity held by non‑affiliates of $8.8 million and had 5,336,350 common shares outstanding as of March 11, 2026. Executive pay for the CEO, CFO and Chief Scientific Officer combines base salary, performance‑based cash bonuses, stock options and performance‑based restricted stock units tied to MIRACLE trial milestones, with some bonuses accrued and earning 8% annual interest until paid.
Moleculin Biotech, Inc. is registering up to 6,367,956 shares of common stock for resale, consisting of shares issuable upon exercise of inducement warrants with an exercise price of $2.3976 per share.
The shares are being registered for the benefit of the selling stockholders and the company will not receive proceeds from resale; the company would receive proceeds only if the warrants are exercised for cash, which at full cash exercise at the initial exercise price would yield gross proceeds of $15.3M. The registration covers shares issuable upon exercise subject to holder-level Beneficial Ownership Limitations of 4.99% or 9.99% (holder election). Shares outstanding were 5,336,350 as of March 11, 2026.
Moleculin Biotech, Inc. filed a prospectus to register up to 6,367,956 shares of its common stock for resale by selling stockholders. The registered shares are issuable upon exercise of newly issued warrants (the “Warrants”) from a February 2026 warrant inducement offer.
Shares outstanding were 5,336,350 as of March 11, 2026. The Warrants have an exercise price of $2.3976 per share, will be exercisable following shareholder approval of the issuance of the Inducement Warrant Shares, and include a Beneficial Ownership Limitation (holders may elect either 4.99% or 9.99%). The company will only receive cash proceeds if holders elect cash exercise; full cash exercise of all underlying warrants at the initial exercise price would result in gross proceeds of $15.3 million.
Moleculin Biotech announced enrollment of the 45th subject in its pivotal Phase 2B/3 MIRACLE trial of Annamycin plus cytarabine (AnnAraC) for adults with relapsed or refractory acute myeloid leukemia. This completes the threshold for an interim data unblinding targeted for mid-2026.
The interim analysis is expected to include about 30 AnnAraC-treated patients and 15 control patients on cytarabine plus placebo, providing early insight into efficacy, safety, and dose selection as the study advances toward its Phase 3 portion and a potential accelerated approval pathway based on complete remission.
Moleculin Biotech, Inc. furnished a new corporate presentation as Exhibit 99.1. The company states this presentation is being used for its corporate presentation and is also posted on its website. The material is provided under Item 7.01 and is furnished, not filed, under the Exchange Act.
Moleculin Biotech reported a 2025 net loss of $33.6M, with research and development expenses of $15.9M and general and administrative plus depreciation and amortization expenses of $9.2M. Cash and cash equivalents were $8.9M as of December 31, 2025, and management expects existing cash plus $8.3M of first‑quarter 2026 financing proceeds to fund operations into the third quarter of 2026.
The company highlighted rapid progress in its pivotal global MIRACLE trial of Annamycin plus cytarabine (AnnAraC) for relapsed or refractory AML. Blinded preliminary data from the first 30 subjects showed a composite complete remission rate of 40%, including 30% complete remission and 10% CRh, across six countries, despite roughly 35% of subjects having prior venetoclax exposure and other high‑risk features. An initial 45‑patient interim unblinding is planned for mid‑2026 as part of the adaptive Phase 2B/3 design.
Moleculin Biotech, Inc. is a late-stage pharmaceutical development company focused on oncology, led by its anthracycline candidate Annamycin. The drug is in the global Phase 2B/3 MIRACLE trial for relapsed/refractory acute myeloid leukemia, with interim data unblindings planned for mid-2026 and the second half of 2026.
Across multiple AML and soft tissue sarcoma lung metastases studies, Annamycin has shown human activity and, in over 90 treated subjects, independent experts have reported no evidence of cardiotoxicity, even above traditional lifetime anthracycline dose limits. The program holds Orphan Drug and Fast Track designations in AML and soft tissue sarcoma.
The company also advances two additional technology portfolios: WP1066, a STAT3-focused immune/transcription modulator platform with externally funded brain tumor trials and encouraging early pediatric data, and WP1122, a glycolysis/glycosylation inhibitor platform with a completed Phase 1a study and a Recommended Phase 2 Dose established.
Moleculin Biotech, Inc. has called a special stockholder meeting on April 15, 2026 to vote on three key items. The main proposal seeks approval, under Nasdaq Listing Rule 5635(d), to allow the exercise of warrants for up to 6,367,956 new common shares at an initial exercise price of $2.3976 per share, which could raise about $15.3 million if fully exercised for cash and would significantly dilute current holders relative to the 4,933,110 shares outstanding as of February 20, 2026. Stockholders will also vote on changing the company’s name to Moleculin Inc. and on authorizing adjournment of the meeting, if needed, to gather additional proxies in favor of the two main proposals.
Moleculin Biotech, Inc. is asking shareholders to approve three proposals at a Special Meeting on April 15, 2026. The primary item seeks shareholder approval to permit up to 6,367,956 shares of common stock to be issued upon exercise of Series H warrants issued February 20, 2026; those Warrants will only become exercisable upon shareholder approval.
The proxy also asks shareholders to approve a corporate name change to Moleculin Inc. and to authorize adjournment of the meeting if additional solicitation of proxies is needed. Shares outstanding were 4,933,110 as of February 20, 2026, and the company states that full cash exercise of the Warrants at the initial exercise price would yield $15.3 million.
Moleculin Biotech entered into warrant exercise inducement agreements with holders of existing warrants to buy up to 2,122,652 shares at $3.90 per share. The company expects aggregate gross proceeds of up to approximately $8.3 million from these exercises before fees.
In return, Moleculin will issue new Series H Inducement Warrants to purchase up to 6,367,956 shares, equal to 300% of the exercised shares. These warrants will have a five-year term and an exercise price per share equal to the lesser of $3.90 and the lowest volume-weighted average price over the five trading days after the public announcement, subject to shareholder approval. The warrants include price-adjustment features with a floor of $0.962, beneficial ownership limits of 4.99% or 9.99%, and cashless exercise under certain conditions.